<VariationArchive VariationID="1075527" VariationName="NM_005670.4(EPM2A):c.108_139del (p.Ala37fs)" VariationType="Deletion" Accession="VCV001075527" Version="6" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-03-17" DateCreated="2021-05-10" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1060626" VariationID="1075527">
      <GeneList>
        <Gene Symbol="EPM2A" FullName="EPM2A glucan phosphatase, laforin" GeneID="7957" HGNC_ID="HGNC:3413" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>6q24.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="145383353" stop="145736023" display_start="145383353" display_stop="145736023" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="145946439" stop="146056990" display_start="145946439" display_stop="146056990" Strand="-" />
          </Location>
          <OMIM>607566</OMIM>
        </Gene>
        <Gene Symbol="EPM2A-DT" FullName="EPM2A divergent transcript" GeneID="100507557" HGNC_ID="HGNC:48990" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>6q24.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="145734869" stop="145886585" display_start="145734869" display_stop="145886585" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="LOC129997381" FullName="ATAC-STARR-seq lymphoblastoid silent region 17642" GeneID="129997381" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>6q24.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="145734995" stop="145735584" display_start="145734995" display_stop="145735584" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_005670.4(EPM2A):c.108_139del (p.Ala37fs)</Name>
      <CanonicalSPDI>NC_000006.12:145735359:CCGCGGTGCCGGCCGGCCTCAGGCGGACGGCACCGCG:CCGCG</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>6q24.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="145735360" stop="145735391" display_start="145735360" display_stop="145735391" variantLength="32" positionVCF="145735359" referenceAlleleVCF="GCCGCGGTGCCGGCCGGCCTCAGGCGGACGGCA" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="146056496" stop="146056527" display_start="146056496" display_stop="146056527" variantLength="32" positionVCF="146056495" referenceAlleleVCF="GCCGCGGTGCCGGCCGGCCTCAGGCGGACGGCA" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>A37fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001360064.2" sequenceAccession="NM_001360064" sequenceVersion="2" change="c.-114+517_-114+548del">
            <Expression>NM_001360064.2:c.-114+517_-114+548del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001627" Type="intron variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000006.11" sequenceAccession="NC_000006" sequenceVersion="11" change="g.146056501_146056532del" Assembly="GRCh37">
            <Expression>NC_000006.11:g.146056501_146056532del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000006.12" sequenceAccession="NC_000006" sequenceVersion="12" change="g.145735365_145735396del" Assembly="GRCh38">
            <Expression>NC_000006.12:g.145735365_145735396del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012832.2" sequenceAccession="NG_012832" sequenceVersion="2" change="g.5465_5496del">
            <Expression>NG_012832.2:g.5465_5496del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001018041.2" sequenceAccession="NM_001018041" sequenceVersion="2" change="c.108_139del">
            <Expression>NM_001018041.2:c.108_139del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001018051.1" sequenceAccession="NP_001018051" sequenceVersion="1" change="p.Ala37fs">
            <Expression>NP_001018051.1:p.Ala37fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001360057.2" sequenceAccession="NM_001360057" sequenceVersion="2" change="c.108_139del">
            <Expression>NM_001360057.2:c.108_139del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001346986.1" sequenceAccession="NP_001346986" sequenceVersion="1" change="p.Ala37fs">
            <Expression>NP_001346986.1:p.Ala37fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001360071.2" sequenceAccession="NM_001360071" sequenceVersion="2" change="c.-562_-531del">
            <Expression>NM_001360071.2:c.-562_-531del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001368129.2" sequenceAccession="NM_001368129" sequenceVersion="2" change="c.-516_-485del">
            <Expression>NM_001368129.2:c.-516_-485del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001368130.1" sequenceAccession="NM_001368130" sequenceVersion="1" change="c.108_139del">
            <Expression>NM_001368130.1:c.108_139del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001355059.1" sequenceAccession="NP_001355059" sequenceVersion="1" change="p.Ala37fs">
            <Expression>NP_001355059.1:p.Ala37fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001368131.1" sequenceAccession="NM_001368131" sequenceVersion="1" change="c.-260_-229del">
            <Expression>NM_001368131.1:c.-260_-229del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_005670.4" sequenceAccession="NM_005670" sequenceVersion="4" change="c.108_139del" MANESelect="true">
            <Expression>NM_005670.4:c.108_139del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_005661.1" sequenceAccession="NP_005661" sequenceVersion="1" change="p.Ala37fs">
            <Expression>NP_005661.1:p.Ala37fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1204045237" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_005670.4(EPM2A):c.108_139del (p.Ala37fs) AND Progressive myoclonic epilepsy" Accession="RCV001389133" Version="4">
        <ClassifiedConditionList TraitSetID="13597">
          <ClassifiedCondition DB="MedGen" ID="C0751778">Progressive myoclonic epilepsy</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-08-17" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_005670.4(EPM2A):c.108_139del (p.Ala37fs) AND Lafora disease" Accession="RCV003447596" Version="3">
        <ClassifiedConditionList TraitSetID="792">
          <ClassifiedCondition DB="MedGen" ID="C0751783">Lafora disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-04-12" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-08-17" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2021-05-10" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11175283</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20738377</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="792" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3139" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Lafora body disorder</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Myoclonic epilepsy of Lafora</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Lafora disease</ElementValue>
                <XRef ID="Lafora+disease/4074" DB="Genetic Alliance" />
                <XRef ID="MONDO:0009697" DB="MONDO" />
                <XRef ID="230425004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Epilepsy progressive myoclonic  2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">LBD</ElementValue>
                <XRef Type="MIM" ID="254780" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">EPM2</ElementValue>
                <XRef Type="MIM" ID="254780" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MELF</ElementValue>
                <XRef Type="MIM" ID="254780" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Progressive myoclonus epilepsy, Lafora type (also known as Lafora disease [LD]) is characterized by focal occipital seizures presenting as transient blindness or visual hallucinations and fragmentary, symmetric, or generalized myoclonus beginning in previously healthy individuals at age eight to 19 years (peak 14-16 years). Generalized tonic-clonic seizures, atypical absence seizures, atonic seizures, and focal seizures with impaired awareness may occur. The course of the disease is characterized by increasing frequency and intractability of seizures. Status epilepticus with any of the seizure types is common. Cognitive decline becomes apparent at or soon after the onset of seizures. Dysarthria and ataxia appear early while spasticity appears late. Emotional disturbance and confusion are common in the early stages of the disease and are followed by dementia. Most affected individuals die within ten years of onset, usually from status epilepticus or from complications related to nervous system degeneration.</Attribute>
                <XRef ID="NBK1389" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8214" />
                <XRef ID="8214" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301563</ID>
                <ID Source="BookShelf">NBK1389</ID>
              </Citation>
              <XRef ID="501" DB="Orphanet" />
              <XRef ID="C0751783" DB="MedGen" />
              <XRef ID="MONDO:0009697" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS254780" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="13597" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3141" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Myoclonus epilepsy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Progressive myoclonus epilepsy</ElementValue>
                <XRef ID="MONDO:0020074" DB="MONDO" />
                <XRef ID="267581004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Familial progressive myoclonic epilepsy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Progressive myoclonic epilepsy</ElementValue>
                <XRef ID="Progressive+myoclonic+epilepsy/9622" DB="Genetic Alliance" />
                <XRef ID="267581004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Myoclonic Epilepsies, Progressive</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7140" />
                <XRef ID="7140" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="NICE, 2022">
                <URL>https://www.nice.org.uk/guidance/ng217</URL>
                <CitationText>UK NICE Guideline NG217, Epilepsies in children, young people and adults, 2022</CitationText>
              </Citation>
              <XRef ID="308" DB="Orphanet" />
              <XRef ID="98261" DB="Orphanet" />
              <XRef ID="C0751778" DB="MedGen" />
              <XRef ID="MONDO:0020074" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS254800" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7813582" SubmissionDate="2023-12-11" DateLastUpdated="2023-12-17" DateCreated="2023-12-17">
        <ClinVarSubmissionID localKey="sa_pathology/molecular_genetics_wch9/vc36409" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV004175515" DateUpdated="2023-12-17" DateCreated="2023-12-17" Type="SCV" Version="1" SubmitterName="Genetics and Molecular Pathology, SA Pathology" OrgID="506043" OrganizationCategory="laboratory" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508197" SubmitterName="Shariant Australia, Australian Genomics" Type="behalf" OrganizationCategory="consortium" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-12-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="EPM2A" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">ALLELE_18459</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_005670.4:c.108_139del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="254780" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>submission_40</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7911755" SubmissionDate="2024-01-26" DateLastUpdated="2024-02-04" DateCreated="2024-02-04">
        <ClinVarSubmissionID localKey="42f1d146b1c3db43a01c18a0d9fa6130b62ed4e16c268f339c2e258a8b3cb094|OMIM:254780" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004235163" DateUpdated="2024-02-04" DateCreated="2024-02-04" Type="SCV" Version="1" SubmitterName="Revvity Omics, Revvity" OrgID="167595" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-04-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_005670.4:c.108_139del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="254780" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14173319</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3116048" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="499547|MedGen:C0751778" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001590377" DateUpdated="2024-02-14" DateCreated="2021-05-10" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-08-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">11175283</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20738377</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20738377</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 1075527). This premature translational stop signal has been observed in individual(s) with clinical features of Lafora disease (PMID: 11175283, 20738377). This variant is present in population databases (no rsID available, gnomAD 0.004%). This sequence change creates a premature translational stop signal (p.Ala37Glyfs*60) in the EPM2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in EPM2A are known to be pathogenic (PMID: 20738377).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="EPM2A" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000006.11:g.146056496_146056527del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0751778" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3116048" TraitType="Disease" MappingType="XRef" MappingValue="C0751778" MappingRef="MedGen">
        <MedGen CUI="C0751778" Name="Progressive myoclonic epilepsy" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7911755" TraitType="Disease" MappingType="XRef" MappingValue="254780" MappingRef="OMIM">
        <MedGen CUI="CN377204" Name="Myoclonic epilepsy of Lafora 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7813582" TraitType="Disease" MappingType="XRef" MappingValue="254780" MappingRef="OMIM">
        <MedGen CUI="CN377204" Name="Myoclonic epilepsy of Lafora 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

